Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-02-24
2001-11-13
Riley, Jezia (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S001000, C514S04400A, C514S077000, C514S277000, C435S006120, C435S007100, C435S007200, C436S518000, C436S528000, C422S051000, C422S067000, C422S082050, C422S082090
Reexamination Certificate
active
06316434
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to an assay for detecting emetic activity in test compounds that are useful as type 4 phospodiesterase (PDE 4) inhibitors. Such compounds have important biological activity and can be used in treating or preventing asthma and other inflammatory diseases and conditions. (Harbinson et al., 1997; Karlsson & Aldous, 1997; Silvestre et al., 1998; Nieman et al., 1998; Nicholson & Shadid, 1994). However, these agents are known to cause emesis in man and in various animal species (Silvestre et al., 1998; Murdoch et al., 1998; Robichaud et al., 1998; Heaslip & Evans, 1995; Humpel et al., 1986; Horowski & Sastre-y-Hernandez, 1985). This debilitating side effect is a great impairment to the therapeutic potential of this new class of drugs.
Consequently, one object of the present invention was to elucidate the mechanism by which PDE 4 inhibitors trigger emesis.
Another object was to provide an assay for emesis that is reliable.
More particularly, an object of the present invention was to investigate the involvement of the noradrenergic nervous system in PDE 4 inhibitor-induced emesis and to provide an assay for emetic activity in these compounds.
Further, this assay is particularly useful for the identification of the locus of action of test compounds.
According to an aspect of the invention, the present assay is useful in identifying a test compound having activity in a cerebral and/or a peripheral locus of action. Therefore it is a useful application to select a test compound that is capable of crossing the blood-brain barrier.
These and other objects will become apparent to those of ordinary skill from the teachings provided herein.
SUMMARY OF THE INVENTION
The present invention encompasses an assay for emetic activity of a PDE 4 inhibiting compound, comprising:
(A) administering to a test mammal an anesthetic compound in an amount sufficient to cause an anesthetic effect;
(B) administering to the test mammal a test compound that has PDE 4 inhibitory activity;
(C) observing the test mammal for changes in the anesthetic effect, and
(D) correlating any change in the anesthetic effect observed in the anesthetized test mammal to a standard.
REFERENCES:
patent: 5608070 (1997-03-01), Alexander et al.
patent: 5632977 (1997-05-01), Chandran et al.
patent: 5710160 (1998-01-01), Guay et al.
patent: 5710170 (1998-01-01), Guay et al.
patent: 6034089 (2000-03-01), Han et al.
A.J. Duplantier et al., J. Med. Chem., 39:120-125 (1996).
L. Sekut et al., Lab. Animal Sci.,45:647-651 (1995).
R.J. Heaslip et al., Eur. J. Pharmacology, 286:281-290(1995).
P.L.R. Andrews and C.J. Davis, “The physiology of emesis induced by anti-cancer therapy,”Serotonin and the Scientific Basis of Anti-emetic Therapy(D.J.M. Reynolds et al., Eds.) pp. 25-49, Oxford Clinical Communications, (Oxford, 1995).
E. Zaller et al., Pharmacopyschiat., 17:188-190 (1984).
C. Correa-Sales et al., J. Pharmacology and Exp. Therapeutics, 263:1046-1049 (1992).
C.D. Nicholson et al., Pulmonary Pharmacology, 7:1-17(1994).
B.V. Clineschmidt et al., J. Pharmacology and Exp. Therapeutics, 245:32-40(1988).
Y. Hikasa et al., Am. J. Vet. Res., 50:1348-1351 (1989).
M. Humpel et al., Arch. Toxicol., 59,Suppl.9:251(1986).
P.L. Harbinson et al., Eur. Respir. J., 10:1008-1014(1997).
T.J. Sylvina et al., Lab. Animal Sci.,40:178-182(1990).
J. Silvestre et al., Drugs of the Future, 23:607-615(1998).
C. Saoie et al., Can. J. Physiol, Pharmacol., 78:708-71(2000).
D.J. Pettibone et al., Arch. Pharmacol., 336:169-175(1987).
R.B. Nieman et al., Am. J. Respir. Crit. Care. Med., 157:A413(1998).
R.D.Murdoch et al., Am. J. Respir. Crit. Care Med., 157:A409(1998).
S.Z. Langer, Pharmacol. Rev., 32:337-362(1981).
Y. Hikasa et al., J. Pharmacology and Exp. Therapeutics,261:746-754(1992).
S. K. Khandker et al., Pharmacol. Res.,29:383-387(1994).
J-A Karlsson et al., Exp. Opin. Ther. Patents,7:989-1003(1997).
N. Japundzic-Zigon et al., Pharmacol.Res.,35:287-297(1997).
R. Horowski et al., Curr. Therapeutic Res.,38:23-29(1985).
Y. Hikasa et al., Eur. J. Pharmacology,229:241-251(1992).
R.E. Fish, “Pharmacology of Injectable Anesthetics,”Anesthesia and Analgesia in Laboratory Animals(D.F. Kohn et al., Eds.) pp. 1-8, Academic Press (New York, 1997).
Chang Chi Chung
Robichaud Annette
Savoie Chantal
Lee Shu M.
Merck Frosst Canada & Co.
Riley Jezia
Rose David L.
LandOfFree
Assay for emetic activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assay for emetic activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assay for emetic activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2614150